Acute Agitation and Aggression Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||921934|
|出版日期||內容資訊||英文 111 Pages
|全球重度躁動·攻擊性治療市場:成長，趨勢，及預測 Acute Agitation and Aggression Treatment Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 111 Pages||
Global Acute Agitation and Aggression Treatment market are expected to witness a CAGR of 4.9% during the forecast period. Certain factors that are driving the market growth include a rise in the burden of mental illness and an increase in agitation in patients, an increase in focus on creating awareness about agitation and aggression, and ongoing research on the development of novel treatment for agitation.
According to the statistics provided by the Mental Health Foundation in 2018, mental health problems are one of the primary causes of rising medical concerns. In addition, according to the United States Census Bureau's Statistics, as of 2017, the total number of people aged 65 and older exceeds 50 million, and between 2020-2030, the number of the elderly population is projected to increase by almost 18 million. Although much smaller in the total size, the number of people aged between 85 years and older is expected to be more than tripled, from an estimated 6 million in 2017 to nearly 20 million by 2060. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the elderly population.
Agitation is generally defined as excessive verbal and/or motor behavior. It can escalate to aggression, which can be either verbal (vicious cursing and threats) or physical (toward objects or people). The scope of the market studied includes the drugs which acutely agitated patients are offered.
Anti-psychotics are Expected to Hold Significant Market Share in the Drug Class Segment
The typical antipsychotics cause sedation, given a high enough dose. Haloperidol, a high potency butyrophenone, has been frequently used as an intramuscular as-needed medication for agitation and aggressive behavior in an emergency department setting for a wide variety of patients. Droperidol, another antipsychotic in the butyrophenone class, is not approved by the US Food and Drug Administration for psychiatric conditions but has been used for sedating agitated patients in an emergency room setting.
North America Dominates the Market and Expected to do Same in the Forecast Period
As per the Mental Health America, more than 44 million American adults have a mental health condition (2017). The most commonly reported agents are benzodiazepines, followed by butyrophenone antipsychotics (e.g., haloperidol, droperidol) as reported by directors of emergency medicine residencies and pediatric emergency medicine fellowships in the United States. Moreover, within the United States, approximately 5.7 million people are living with dementia (Alzheimer's Association, 2018). All these factors are expected to drive market growth in the region.
The global acute agitation and aggression treatment market is moderately competitive and consists of a few major players. Companies like Eli Lilly and Company, Pfizer, Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Bristol-Myers Squibb, among others, hold the substantial market share in the Acute Agitation and Aggression Treatment market.